Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Non-Current Assets (2016 - 2025)

Voyager Therapeutics (VYGR) has disclosed Non-Current Assets for 11 consecutive years, with $49.6 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets fell 57.34% to $49.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $320.6 million through Dec 2025, up 12.9% year-over-year, with the annual reading at $49.6 million for FY2025, 57.34% down from the prior year.
  • Non-Current Assets hit $49.6 million in Q4 2025 for Voyager Therapeutics, down from $68.7 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $116.2 million in Q4 2024 to a low of $31.6 million in Q4 2023.
  • Historically, Non-Current Assets has averaged $56.7 million across 5 years, with a median of $54.1 million in 2022.
  • Biggest five-year swings in Non-Current Assets: soared 267.89% in 2024 and later crashed 57.34% in 2025.
  • Year by year, Non-Current Assets stood at $57.2 million in 2021, then plummeted by 39.02% to $34.9 million in 2022, then dropped by 9.35% to $31.6 million in 2023, then skyrocketed by 267.89% to $116.2 million in 2024, then plummeted by 57.34% to $49.6 million in 2025.
  • Business Quant data shows Non-Current Assets for VYGR at $49.6 million in Q4 2025, $68.7 million in Q3 2025, and $94.2 million in Q2 2025.